Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers

Journal of Rheumatology

Volumn 26, Issue 2, 1999, Pages 251-258

  Keyszer, Gernot ^a   Lambiri, Irini ^b   Nagel, Rainhold ^b   Keysser, Christa ^b   Keysser, Martin ^b   Gromnica Ihle, Erika ^b   Franz, Juliane ^b   Burmester, Gerd R ^b   Jung, Klaus ^b  

^a MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^b NONE

Author keywords

Matrix Metalloproteinases; Rheumatoid Arthritis; Surrogate Markers

Indexed keywords

C REACTIVE PROTEIN; COLLAGENASE; DEOXYPYRIDINOLINE; INTERLEUKIN 2; INTERLEUKIN 6; PYRROLIDINE DERIVATIVE; RHEUMATOID FACTOR; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; CONNECTIVE TISSUE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE MARKER; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS;

ARTHRITIS; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; BIOLOGICAL MARKERS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; COHORT STUDIES; COLLAGENASES; CYTOKINES; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 3; METHOTREXATE; MIDDLE AGED; RHEUMATOID FACTOR; TIME FACTORS; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 0032926067     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Wollheim FA, Eberhardt KB. The search for laboratory measures of outcome in rheumatoid arthritis. Baillieres Clin Rheumatol 1992;6:69-93.
2. Keyszer G, Heer AH, Gay S. Cytokines and oncogenes in cellular interactions of rheumatoid arthritis. Stem Cells 1994;12:75-86.
3. Ishiguro N, Ito T, Ohata K, Fujimoto N, Iwata H. Determination of stromelysin-1, 72 and 92 kDa type IV collagenase, tissue inhibitor of metalloproteinase-1 (TIMP-1), and TIMP-2 in synovial fluid and serum from patients with rheumatoid arthritis. J Rheumatol 1996;23:1599-604.
4. Clark IM, Powell LK, Ramsey S, Hazleman BL, Cawston TE. The measurement of collagenase, tissue inhibitor of metalloproteinases (TIMP), and collagenase-TIMP complex in synovial fluids from patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum 1993;36:372-9.
5. Yoshihara Y, Obata K, Fujimoto N, Yamashita K, Hayakawa T, Shimmei M. Increased levels of stromelysin-1 and tissue inhibitor of metalloproteinases-1 in sera from patients with rheumatoid arthritis. Arthritis Rheum 1995;38:969-75.
6. Arvidson NG, Gudbjornsson B, Elfman L, Ryden AC, Totterman TH, Hallgren R. Circadian rhythm of serum interleukin-6 in rheumatoid arthritis. Ann Rheum Dis 1994;53:521-4.
7. van Leeuwen MA, Westra J, Limburg PC, van Riel PL, van Rijswijk MH. Clinical significance of interleukin-6 measurement in early rheumatoid arthritis: relation with laboratory and clinical variables and radiological progression in a three year prospective study. Ann Rheum Dis 1995;54:674-7.
8. Manicourt DH, Triki R, Fukuda K, DeVogelaer JP, Nagant de Deuxchaisnes J, Thonar EJ. Levels of circulating tumor necrosis factor alpha and interleukin-6 in patients with rheumatoid arthritis. Relationship to serum levels of hyaluronan and antigenic keratan sulfate. Arthritis Rheum 1993;36:490-9.
9. Espersen GT, Vestergaard M, Ernst E, Grunnet N. Tumour necrosis factor alpha and interleukin-2 in plasma from rheumatoid arthritis patients in relation to disease activity. Clin Rheumatol 1991;10:374-6.
10. Okamoto H, Yamamura M, Morita Y, Harada S, Makino H, Ota Z. The synovial expression and serum levels of interleukin-6, interleukin-11, leukemia inhibitory factor, and oncostatin M in rheumatoid arthritis. Arthritis Rheum 1997;40:1096-105.
11. Beckham JC, Caldwell DS, Peterson BL, et al. Disease severity in rheumatoid arthritis: relationships of plasma tumor necrosis factor-alpha, soluble interleukin 2-receptor, soluble CD4/CD8 ratio, neopterin, and fibrin D-dimer to traditional severity and functional measures. J Clin Immunol 1992;12:353-61.
12. Dasgupta B, Corkill M, Kirkham B, Gibson T, Panayi G. Serial estimation of interleukin 6 as a measure of systemic disease in rheumatoid arthritis. J Rheumatol 1992;19:22-5.
13. Altomonte L, Zoli A, Mirone L, Scolieri P, Magaro M. Serum levels of interleukin-1b, tumour necrosis factor-a and interleukin-2 in rheumatoid arthritis. Correlation with disease activity. Clin Rheumatol 1992;11:202-5.
14. Burmester GR, Stuhlmuller B, Keyszer G, Kinne RW. Mononuclear phagocytes and rheumatoid synovitis: Mastermind or workhorse in arthritis? Arthritis Rheum 1997;40:5-18.
15. Wollheim FA. Predictors of joint damage in rheumatoid arthritis. APMIS 1996;104:81-93.
16. Paimela L, Leirisalo Repo M, Risteli L, Hakala M, Helve T, Risteli J. Type I collagen degradation product in serum of patients with early rheumatoid arthritis: relationship to disease activity and radiological progression in a 3-year follow-up. Br J Rheumatol 1994;33:1012-6.
17. Hein G, Franke S, Muller A, Braunig E, Eidner T, Stein G. The determination of pyridinium crosslinks in urine and serum as a possible marker of cartilage degradation in rheumatoid arthritis. Clin Rheumatol 1997;16:167-72.
18. Spector TD, James IT, Hall GM, Thompson PW, Perrett D, Hart DJ. Increased levels of urinary collagen crosslinks in females with rheumatoid arthritis. Clin Rheumatol 1993;12:240-4.
19. Gevers G, Devos P, De Roo M, Dequeker J. Increased levels of osteocalcin (serum bone Gla-protein) in rheumatoid arthritis. Br J Rheumatol 1986;25:260-2.
20. Pietschmann P, Machold KP, Wolosczuk W, Smolen JS. Serum osteocalcin concentrations in patients with rheumatoid arthritis. Ann Rheum Dis 1989;48:654-7.
21. Mattei JP, Ferrera V, Boutsen Y, et al. Serum and synovial fluid osteocalcin in rheumatic diseases. Int J Clin Pharmacol Res 1992;12:103-7.
22. Siede WH, Seiffert UB, Merle S, Goll HG, Oremek G. Alkaline phosphatase isoenzymes in rheumatic diseases. Clin Biochem 1989;22:121-4.
23. Eggelmeijer F, Papapoulos SE, Westedt ML, Van Paassen HC, Dijkmans BA, Breedveld FC. Bone metabolism in rheumatoid arthritis: relation to disease activity. Br J Rheumatol 1993;32:387-91.
24. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
25. Altman RD. Criteria for classification of clinical osteoarthritis. J Rheumatol 1991;18 Suppl 27:10-2.
26. Altman R, Alarcon G, Appelrouth D, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum 1991;34:505-14.
27. Tan EM, Cohen AS, Fries JF, el al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
28. Bennett RM. Psoriatic arthritis. In: Koopman WJ, editor. Arthritis and allied conditions: a textbook of rheumatology. Baltimore: Williams & Wilkins; 1997:1229-44.
29. Goie T, Steven MM, van der Linden SM, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a comparison of the Rome, New York and modified New York criteria in patients with a positive clinical history screening test for ankylosing spondylitis. Br J Rheumatol 1985;24:242-9.
30. Doria A, Ghirardello A, de Zambiasi P, Ruffatti A, Gambari PF. Japanese diagnostic criteria for mixed connective tissue disease in Caucasian patients. J Rheumatol 1992;19:259-64.
31. Masi AT, Rodnan GP, Medsger TA Jr. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
32. Fuchs HA, Pincus T. Reduced joint counts in controlled clinical trials in rheumatoid arthritis. Arthritis Rheum 1994;37:470-5.
33. van Leeuwen MA, van der Heijde DM, van Rijswijk MH, et al. Interrelationship of outcome measures and process variables in early rheumatoid arthritis. A comparison of radiologic damage, physical disability, joint counts, and acute phase reactants. J Rheumatol 1994;21:425-9.
34. Lansbury J. Report of a three-year study on the systemic and articular indices in rheumatoid arthritis. Arthritis Rheum 1959;2:505-22.
35. Keitel W, Hoffman H, Weber G, et al. Ermittlung der prozentualen Funktionsminderung der Gelenke durch einen Bewegungsfunktionstest in der Rheumatologie [Determination of the relative loss of joint function by a joint function test in rheumatology]. Dtsch Gesundheitsw. 1971;26:1901-3.
36. Eberl DR, Fasching V, Rahlfs V, Schleyer I, Wolf R. Repeatability and objectivity of various measurements in rheumatoid arthritis. Arthritis Rheum 1976;19:1278-86.
37. Kalla AA, Smith PR, Brown GM, Meyers OL, Chalton D. Responsiveness of Keitel functional index compared with laboratory measures of disease activity in rheumatoid arthritis. Br J Rheumatol 1995;34:141-9.
38. Lein M, Nowak L, Jung K, et al. Analytical aspects regarding the measurement of metalloproteinases and their inhibitors in blood. Clin Biochem 1997;30:491-6.
39. Tietz NW, Rinker AD, Shaw LM. IFCC method for alkaline phosphatase. J Clin Chem Clin Biochem 1983;21:731-8.
40. Keysser M, Nagel R. Eine neue Methode zur Bestimmung des Hydroxyprolins und des "collagen like protein" im serum [A new method for the measurement of hydroxyproline and "collagen like protein" in serum]. Dtsch Gesundheitsw. 1975;30:2289-91.
41. Gravallese EM, Darling JM, Ladd AL, Katz JN, Glimcher LH. In situ hybridization studies of stromelysin and collagenase messenger RNA expression in rheumatoid synovium. Arthritis Rheum 1991;34:1076-84.
42. Keyszer G, Redlich A, Häupl T, et al. Differential expression of cathepsins B and L compared to metalloproteinases and their respective inhibitors in rheumatoid arthritis and osteoarthritis. A parallel investigation by semiquantitative RT-PCR and immunohistochemistry. Arthritis Rheum 1998:(in press).
43. Okada Y, Takeuchi N, Tomita K, Nakanishi I, Nagase H. Immunolocalization of matrix metalloproteinase 3 (stromelysin) in rheumatoid synovioblasts (B cells): correlation with rheumatoid arthritis. Ann Rheum Dis 1989;48:645-53.
44. Okada Y, Gonoji Y, Nakanishi I, Nagase H, Hayakawa T. Immunohistochemical demonstration of collagenase and tissue inhibitor of metalloproteinases (TIMP) in synovial lining cells of rheumatoid synovium. Virchows Arch B Cell Pathol Incl Mol Pathol 1990;59:305-12.
45. Cheung NT, Mattey DL, Dawes PT. Serum pro-matrix metalloproteinase 3 in rheumatoid arthritis: a reflection of local or systemic inflammation. Arthritis Rheum 1996;39:884-5.
46. Manicourt DH, Fujimoto N, Obata K, Thonar EJ. Levels of circulating collagenase, stromelysin-1, and tissue inhibitor of matrix metalloproteinases 1 in patients with rheumatoid arthritis. Relationship to serum levels of antigenic keratan sulfate and systemic parameters of inflammation. Arthritis Rheum 1995;38:1031-9.
47. Manicourt DH, Fujimoto N, Obata K, Thonar EJ. Serum levels of collagenase, stromelysin-1, and TIMP-1. Age- and sex-related differences in normal subjects and relationship to the extent of joint involvement and serum levels of antigenic keratan sulfate in patients with osteoarthritis. Arthritis Rheum 1994;37:1774-83.
48. Maeda S, Sawai T, Uzuki M, et al. Determination of interstitial collagenase (MMP-1) in patients with rheumatoid arthritis. Ann Rheum Dis 1995;54:970-5.
49. Barrera P, Boerbooms AM, Janssen EM, et al. Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor alpha, and interleukin-6 levels in rheumatoid arthritis. Longitudinal evaluation during methotrexate ard azathioprine therapy. Arthritis Rheum 1993;36:1070-9.
50. Madhok R, Crilly A, Watson J, Capell HA. Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis 1993;52:232-4.
51. MacNaul KL, Chartrain N, Lark M, Tocci MJ, Hutchinson NI. Discoordinate expression of stromelysin, collagenase, and tissue inhibitor of metalloproteinases-1 in rheumatoid human synovial fibroblasts. Synergistic effects of interleukin-1 and tumor necrosis factor-alpha on stromelysin expression. J Biol Chem 1990;265:17238-45.
52. Gough AK, Peel NF, Eastell R, Holder RL, Lilley J, Emery P. Excretion of pyridinium crosslinks correlates with disease activity and appendicular bone loss in early rheumatoid arthritis Ann Rheum Dis 1994;53:14-7.
53. Seibel MJ, Duncan A, Robins SP. Urinary hydroxy-pyridinium crosslinks provide indices of cartilage and bone involvement in arthritic diseases. J Rheumatol 1989;16:964-70.